Top Drugs Losing Patent Exclusivity in 2021 | McDonnell Boehnen Hulbert & Berghoff LLP
To embed, copy and paste the code into your website or blog: Earlier this month, Eric Sagonowsky reviewed the top ten drugs in the U.S. (in terms of sales) losing patent exclusivity in an article published by These drugs are Lucentis (Genentech/Roche), Bystolic (AbbVie/Allergan), Vascepa (Amarin), Nothera (Lundbeck), Narcan (Emergent Biosolutions), Brovana (Sunovion), Sutent (Pfizer), Saphris (AbbVie/Allergan), Amitiza (Mallinckrodt), and Feraheme (Amag Pharma). The nature of these losses and consequences thereof can be seen from the article, synopsized here. Lucentis (ranibizumab), Roche'...
Source: jdsupra.com